Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 5,141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV Infections
Interventions: FITT: Family Intervention - Telephone Tracking; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GW873140; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 52
States / cities: Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 43 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 10 more

Conditions: Microbial Colonization
Interventions: No intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 24 Years · Female only
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV
Interventions: Fecal Microbiota; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Antiretroviral therapy; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 16 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Heavy Drinking, HIV, Alcohol Dependence
Interventions: Topiramate, Medical Management, Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Groton, Connecticut • Bethesda, Maryland

Conditions: HIV, Sexually Transmitted Infections
Interventions: Latino STYLE; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 14 Years and older
Enrollment: 542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hepatitis C Infection
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 44
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: SB-728mR-T, Cyclophosphamide; Genetic · Drug
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Norwalk, Connecticut • Orlando, Florida + 2 more

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: L-743,872; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rahway, New Jersey

Conditions: HIV
Interventions: Geenius HIV1/2 Supplemental Assay; Device
Lead sponsor: Bio-Rad Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Silver Spring, Maryland + 1 more

Conditions: Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Cryptosporidium Immune Whey Protein Concentrate (Bovine); Drug
Lead sponsor: Univax Biologics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more

Conditions: Neuropathic Pain, HIV Neuropathy, HIV/AIDS, Pain
Interventions: Standard Acupuncture / Moxibustion, Individualized (Tailored) Active Acupuncture / Moxibustion; Other
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Pregnancy
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 5
States / cities: Miami, Florida • Detroit, Michigan • Memphis, Tennessee

Conditions: Pre-Exposure Prophylaxis
Interventions: video informational/educational intervention; Other
Lead sponsor: The Alternative Sexualities Health Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rio Vista, California

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Hepatitis C, HIV
Interventions: Ribavirin, Ribavirin plus Abacavir (ABC); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV/AIDS, Substance Use, Bisexuality
Interventions: HIV and substance use prevention; Behavioral
Lead sponsor: Rosalind Franklin University of Medicine and Science; Other
Eligibility: 14 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: HIV Infections
Interventions: Tipranavir, Darunavir, Ritonavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 9
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Miami, Florida + 5 more

Search by objective public record fields.

Effectiveness of a Telephone Intervention Program in Improving Depression, Coping, and Family Functioning in HIV-Infected Individuals and Caregivers

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women

Fecal Microbiota Transplantation in HIV

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers

A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy

Randomized Control Trial of Family-Based HIV Prevention for Latinos

Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay

Efficacy of Elevated CD4 Counts on CMV Retinitis

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain

Determination of HIV-1 Production by the Prostate

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

HIV Pre-Exposure Prophylaxis Among an Unrecognized Sexual Minority Population

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

Understanding and Reducing HIV Risk Behavior and Substance Use Among Self-identified Bisexual Adolescent Men

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI